Study details
Enrolling now
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease
Massachusetts General Hospital
NCT IDNCT05904132ClinicalTrials.gov data as of Apr 2026
Target enrollment
70
Study length
about 1.4 years
Ages
50–80
Locations
1 site in MA
About this study
Researchers are testing a device called tACS to see if it can help people with mild cognitive impairment, which may be related to Alzheimer's disease. The trial will involve using an EEG and questionnaires to monitor participants during trial visits. The goal is to assess how this closed-loop neuromodulation impacts natural gamma rhythms in patients with AD-MCI and their cognitive performance.
Based on ClinicalTrials.gov records.
What participants do
- 1.Use tACS device
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low6%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Neurology